Principal Financial Group Inc. reduced its holdings in Health Catalyst, Inc. (NASDAQ:HCAT – Free Report) by 15.8% in the first quarter, the company said in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,562 shares of the company after selling 5,162 shares during the period. Principal Financial Group Inc.’s holdings in Health Catalyst were worth $208,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in HCAT. Los Angeles Capital Management LLC acquired a new stake in Health Catalyst during the fourth quarter worth approximately $108,000. Tower Research Capital LLC TRC increased its stake in Health Catalyst by 285.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 12,018 shares of the company’s stock worth $111,000 after purchasing an additional 8,900 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Health Catalyst by 23.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,072 shares of the company’s stock worth $140,000 after purchasing an additional 2,817 shares during the last quarter. Mackenzie Financial Corp acquired a new stake in Health Catalyst during the fourth quarter worth approximately $172,000. Finally, Semanteon Capital Management LP acquired a new stake in Health Catalyst during the fourth quarter worth approximately $197,000. 85.00% of the shares are held by institutional investors and hedge funds.
Wall Street analysts weigh in
A number of research firms have recently commented on HCAT. Piper Sandler lowered their price target on shares of Health Catalyst from $15.00 to $14.00 and set an “overweight” rating on the company in a research note on Thursday, June 6th. Canaccord Genuity Group affirmed a “buy” rating and set an $11.00 price target on shares of Health Catalyst in a research note on Tuesday, May 21st. Wells Fargo & Company lowered their price target on shares of Health Catalyst from $14.00 to $13.00 and set an “overweight” rating on the company in a research note on Friday, May 10th. Cantor Fitzgerald affirmed an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a research note on Wednesday, April 10th. Finally, KeyCorp affirmed a “sector weight” rating on shares of Health Catalyst in a research note on Wednesday, April 10th. Three equities analysts have rated the stock with a hold rating and eight have given the company a buy rating. Health Catalyst currently has an average rating of “Moderate Buy” and a consensus target price of $12.09, according to MarketBeat.
View our latest Health Catalyst research report
Health Catalyst shares rise 0.2%
HCAT shares opened at $6.19 on Monday. Health Catalyst, Inc. has a 12-month low of $5.45 and a 12-month high of $14.37. The company has a market cap of $365.40 million, a price-to-earnings ratio of -3.35, and a beta of 1.32. The company has a 50-day moving average of $6.50 and a 200-day moving average of $7.81.
Health Catalyst (NASDAQ:HCAT – Get Free Report) last released its quarterly earnings results on Thursday, May 9. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The company had revenue of $74.72 million for the quarter, compared to the consensus estimate of $74.81 million. Health Catalyst had a negative net margin of 35.56% and a negative return on equity of 11.86%. On average, analysts expect Health Catalyst, Inc. to post -0.4 EPS for the current year.
About Health Catalyst
(Free Report)
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. The company operates in two segments: Technology and Professional Services. The company provides an operating system data platform that provides customers with a comprehensive environment to integrate and organize data from their disparate software systems; and Analytics Applications, a software analytics application built on a data platform to analyze the face of customers in clinical and quality, population health, and financial and operational use cases.
Recommended Articles
Get daily news and reviews for Health Catalyst – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings on Health Catalyst and related companies with MarketBeat.com’s FREE daily email newsletter.
